ChromaDex (NASDAQ:CDXC) Stock Rating Upgraded by StockNews.com

ChromaDex (NASDAQ:CDXC - Get Free Report) was upgraded by research analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a research note issued to investors on Wednesday.

A number of other research firms have also recently weighed in on CDXC. Roth Mkm raised their price target on ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. HC Wainwright raised their target price on ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a research note on Monday, November 4th.

ChromaDex Stock Up 2.6 %

NASDAQ:CDXC traded up $0.14 during trading hours on Wednesday, reaching $5.44. The company had a trading volume of 196,968 shares, compared to its average volume of 553,811. The stock has a 50-day moving average of $5.97 and a two-hundred day moving average of $4.13. ChromaDex has a one year low of $1.36 and a one year high of $7.97. The firm has a market capitalization of $415.52 million, a PE ratio of 544.54 and a beta of 2.15.

ChromaDex (NASDAQ:CDXC - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. The firm had revenue of $25.58 million for the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same period in the previous year, the business earned ($0.01) earnings per share. As a group, sell-side analysts expect that ChromaDex will post 0.04 earnings per share for the current year.

Insider Activity at ChromaDex

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the company's stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the transaction, the director now owns 244,179 shares of the company's stock, valued at $1,511,468.01. This represents a 13.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 9.64% of the stock is currently owned by company insiders.

Institutional Trading of ChromaDex

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. OneDigital Investment Advisors LLC boosted its stake in shares of ChromaDex by 5.5% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company's stock valued at $217,000 after purchasing an additional 3,097 shares during the last quarter. MetLife Investment Management LLC lifted its holdings in ChromaDex by 39.3% in the third quarter. MetLife Investment Management LLC now owns 18,114 shares of the company's stock valued at $66,000 after buying an additional 5,115 shares during the period. The Manufacturers Life Insurance Company boosted its stake in ChromaDex by 75.4% in the third quarter. The Manufacturers Life Insurance Company now owns 19,732 shares of the company's stock valued at $72,000 after acquiring an additional 8,485 shares during the last quarter. Merriman Wealth Management LLC acquired a new stake in ChromaDex during the 2nd quarter worth $32,000. Finally, FMR LLC acquired a new stake in ChromaDex during the 3rd quarter worth $55,000. 15.41% of the stock is currently owned by institutional investors and hedge funds.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.